{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:07:43Z","timestamp":1787065663907,"version":"build-2736575974"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T00:00:00Z","timestamp":1340323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0038744","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T19:34:41Z","timestamp":1340393681000},"page":"e38744","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":93,"title":["Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity"],"prefix":"10.1371","volume":"7","author":[{"given":"Matthias","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Kl\u00f6ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko G.","family":"Niessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bl\u00fcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.","volume":"368","author":"DJ Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.","volume":"124","author":"MA Nauck","year":"2011","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-004-1342-6","article-title":"Incretins, insulin secretion and Type 2 diabetes mellitus.","volume":"47","author":"T Vilsb\u00f8ll","year":"2004","journal-title":"Diabetologia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1463-1326.2011.01386.x","article-title":"The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.","volume":"13","author":"T Forst","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment.","volume":"60","author":"W Kim","year":"2008","journal-title":"Pharmacol Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.","volume":"287","author":"JJ Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.","volume":"29","author":"M Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc07-0233","article-title":"Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.","volume":"30","author":"B Ahr\u00e9n","year":"2007","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.","volume":"144","author":"L Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","article-title":"Glucagon-like peptide-1 prevents beta cell glucolipotoxicity.","volume":"47","author":"J Buteau","year":"2004","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/en.2004-0015","article-title":"Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.","volume":"145","author":"PL Brubaker","year":"2004","journal-title":"Endocrinology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.49.5.741","article-title":"Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.","volume":"49","author":"DA Stoffers","year":"2000","journal-title":"Diabetes"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1677\/jme.0.0290347","article-title":"Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.","volume":"29","author":"A Bulotta","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1517\/13543780903463862","article-title":"Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.","volume":"19","author":"CF Deacon","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","article-title":"(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.","volume":"325","author":"L Thomas","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1211\/jpp.61.01.0008","article-title":"Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.","volume":"61","author":"H Fuchs","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.","volume":"38","author":"S Blech","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1463-1326.2009.01046.x","article-title":"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.","volume":"11","author":"T Heise","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.","volume":"12","author":"AJ Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1210\/jc.2007-1369","article-title":"Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.","volume":"93","author":"K Azuma","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20100372","article-title":"Sitagliptin prevents the development of metabolic and hormonal disturbances, increased \u03b2-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.","volume":"120","author":"B Maiztegui","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2337\/diabetes.51.4.943","article-title":"Long-term treatment with the dipeptidyl peptidase IV inhibitor P32\/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa\/fa) Zucker rats.","volume":"51","author":"JA Pospisilik","year":"2002","journal-title":"Diabetes"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db10-1338","article-title":"Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.","volume":"60","author":"J Shirakawa","year":"2011","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e1000938","DOI":"10.1371\/journal.pgen.1000938","article-title":"Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance.","volume":"6","author":"J Mauer","year":"2010","journal-title":"PLoS Genet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","article-title":"Estimation of metabolite concentrations from localized in vivo proton NMR spectra.","volume":"30","author":"SW Provencher","year":"1993","journal-title":"Magn Reson Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/11207400-000000000-00000","article-title":"Linagliptin: in type 2 diabetes mellitus.","volume":"71","author":"LJ Scott","year":"2011","journal-title":"Drugs"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of \u03b2-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.","volume":"13","author":"S Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.","volume":"13","author":"MR Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.","volume":"13","author":"R Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref30","first-page":"585","article-title":"Pathophysiology and pharmacological treatment of insulin resistance.","volume":"21","author":"S Matthaei","year":"2000","journal-title":"Endocr Rev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease.","volume":"16","author":"E Bugianesi","year":"2010","journal-title":"Curr Pharm Des"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ncpendmet0190","article-title":"Mechanisms of Disease: hepatic steatosis in type 2 diabetes\u2013pathogenesis and clinical relevance.","volume":"2","author":"M Roden","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MOL.0b013e3283321d37","article-title":"Thiazolidinediones and the liver in humans.","volume":"20","author":"H Yki-J\u00e4rvinen","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1474-9726.2011.00786.x","article-title":"Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.","volume":"11","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2012","journal-title":"Aging Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.23861","article-title":"Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity.","volume":"52","author":"N Sachithanandan","year":"2010","journal-title":"Hepatology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0038744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T18:30:36Z","timestamp":1540233036000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0038744"}},"subtitle":[],"editor":[{"given":"Jose A. L.","family":"Calbet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,22]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0038744","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,22]]}}}